Kenvue Inc. $KVUE Holdings Lowered by Keybank National Association OH

Keybank National Association OH lessened its position in Kenvue Inc. (NYSE:KVUE) by 16.6% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 709,413 shares of the company’s stock after selling 141,143 shares during the period. Keybank National Association OH’s holdings in Kenvue were worth $12,528,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Johnson Financial Group Inc. acquired a new position in shares of Kenvue during the second quarter worth about $26,000. GK Wealth Management LLC purchased a new position in Kenvue during the third quarter worth about $27,000. CoreCap Advisors LLC raised its holdings in Kenvue by 64.9% during the second quarter. CoreCap Advisors LLC now owns 1,502 shares of the company’s stock worth $29,000 after purchasing an additional 591 shares in the last quarter. Bell Investment Advisors Inc acquired a new stake in Kenvue in the second quarter valued at about $35,000. Finally, Bank Julius Baer & Co. Ltd Zurich acquired a new stake in Kenvue in the third quarter valued at about $36,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Price Performance

Shares of NYSE KVUE opened at $19.31 on Thursday. The firm has a market capitalization of $37.09 billion, a P/E ratio of 21.94, a PEG ratio of 1.77 and a beta of 0.48. Kenvue Inc. has a one year low of $14.06 and a one year high of $20.13. The company’s fifty day moving average is $18.43 and its two-hundred day moving average is $18.27. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.71 and a current ratio of 1.01.

Kenvue (NYSE:KVUE) last posted its quarterly earnings results on Friday, October 30th. The company reported $0.29 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.29. The business had revenue of $3.89 billion for the quarter, compared to analysts’ expectations of $3.86 billion. Kenvue had a net margin of 10.76% and a return on equity of 21.22%. The business’s revenue for the quarter was up 3.2% on a year-over-year basis. During the same period in the prior year, the company posted $0.28 EPS. Analysts forecast that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, October 2nd. Investors of record on Monday, September 21st were paid a $0.21 dividend. The ex-dividend date was Monday, September 21st. This represents a $0.84 annualized dividend and a dividend yield of 4.4%. Kenvue’s dividend payout ratio (DPR) is 95.45%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Kenvue in a report on Friday, September 11th. Barclays boosted their target price on Kenvue from $18.00 to $19.00 and gave the stock an “equal weight” rating in a research report on Tuesday, July 21st. Wall Street Zen downgraded Kenvue from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. UBS Group increased their target price on Kenvue from $19.00 to $20.00 and gave the stock a “neutral” rating in a research note on Monday, November 2nd. Finally, HSBC reduced their price target on Kenvue from $20.00 to $19.00 and set a “hold” rating for the company in a report on Monday, August 10th. Ten investment analysts have rated the stock with a Hold rating. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $19.29.

Kenvue Company Profile

Kenvue Inc. is a consumer health company that develops and sells products for everyday health and personal care. Its portfolio includes over-the-counter medicines, skin and hair care, oral care, wound care, and baby care products. Its well-known brands include Tylenol, Neutrogena, Aveeno, Listerine, Band-Aid, Johnson’s, and Zyrtec. Kenvue organizes its business around Self Care, Skin Health and Beauty, and Essential Health. The company became an independent business in 2023 after Johnson & Johnson completed the separation of its consumer health business.